Clinical Trial Search

Primary: Change From Baseline in Glycosylated Haemoglobin (HbA1c) — -0.23; -0.23; -0.32; 0.01 Percent (%) glycosylated haemoglobin — p=< 0.0001

Primary: Percentage of Genotype 1b Participants With Sustained Virologic Response at Follow-up Week 12 (SVR12) — 85.1; 81.3 Percentage of participants

Primary: Mean Change in Best Corrected Visual Acuity (BCVA) at Month 12 Compared to Baseline — 12.3 Letters

Primary: Change From Baseline of Forced Vital Capacity — 5.5; 4.7; 0.9 percentage change from baseline

Primary: Percentage of Participants With Remission at Week 8 — 16.6; 3.6 percentage of participants — p=0.0005

Primary: Mean Change in Visual Acuity From Baseline — 2.8; 0.2 letters

Primary: Point Prevalence Abstinence — 15; 5 participants

Primary: Grading Scale for Visual Evaluation of Skin Condition — 0; 0; 0; 0 Scores Ranging (0-7)

Primary: Change in Intraocular Pressure From Baseline to Week 12 — 6.12; 6.91 mm Hg — p=<0.01

Primary: Percentage of Participants With Undetectable Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) 24 Weeks After Completing Study Treatment (SVR24) — 86.7; 88.3 Percentage of…

Primary: Days Alive and Outside of Hospital — 180; 178 Days

Primary: Relative Change From Baseline at One Year (12 Months) in Mean Lumbar Spine (L2 - L4) Bone Mineral Density — 3.7427; 4.3395; 4.0328; 4.7611 Percent change — p=0.045

Primary: Percentage of Participants Taking Greater Than (>) 1200 Milligram (mg) (>3 Caplets) on no More Than 2 Use Days During the Study — 95.2 percentage of participants

Primary: Change From Baseline in Total Nasal Symptom Score (TNSS) During 2 Weeks of Therapy — -1.41; -0.59 units on a scale — p=<0.001

Primary: Mean Score Change in Fatigue Measured With Brief Fatigue Inventory From Baseline to 4 Weeks — -0.96; -1.11 units on a scale — p=0.57